News coverage about Intra-Cellular Therapies (NASDAQ:ITCI) has been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Intra-Cellular Therapies earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.1595518012677 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment’s analysis:
- Intra-Cellular Therapies (ITCI) Upgraded at ValuEngine (americanbankingnews.com)
- Intra-Cellular Therapies, Inc. (ITCI) Stock Price trades 49.08% off from 200- SMA – Nasdaq Chronicle (nasdaqchronicle.com)
- Intra-Cellular Therapies to Present at the Cowen and Company 38th Annual Health Care Conference (markets.financialcontent.com)
- Intra-Cellular Therapies, Inc. (ITCI) predicted -1.60% EPS growth for next year – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Intra-Cellular Therapies Inc Forecasted to Earn FY2018 Earnings of ($3.95) Per Share (ITCI) (americanbankingnews.com)
Several equities research analysts recently weighed in on the company. ValuEngine raised Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research note on Wednesday, March 7th. Leerink Swann reaffirmed an “outperform” rating on shares of Intra-Cellular Therapies in a research note on Sunday, March 4th. SunTrust Banks reaffirmed a “buy” rating and issued a $28.00 price target on shares of Intra-Cellular Therapies in a research note on Friday, March 2nd. Zacks Investment Research downgraded Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a report on Tuesday, March 6th. Finally, JPMorgan Chase & Co. assumed coverage on Intra-Cellular Therapies in a report on Monday, February 26th. They issued an “overweight” rating and a $25.00 target price on the stock. Two analysts have rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company’s stock. Intra-Cellular Therapies has an average rating of “Buy” and a consensus price target of $27.09.
Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.06). Intra-Cellular Therapies had a negative net margin of 39,745.53% and a negative return on equity of 26.67%. The business had revenue of $5.06 million for the quarter, compared to the consensus estimate of $0.05 million. During the same period in the previous year, the company earned ($0.64) earnings per share. The company’s revenue for the quarter was down 94.8% compared to the same quarter last year. equities analysts predict that Intra-Cellular Therapies will post -3.33 EPS for the current fiscal year.
In other Intra-Cellular Therapies news, VP Lawrence J. Hineline sold 49,700 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $20.02, for a total value of $994,994.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Michael Halstead sold 25,500 shares of the stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $18.03, for a total value of $459,765.00. Following the completion of the transaction, the senior vice president now directly owns 191 shares in the company, valued at approximately $3,443.73. The disclosure for this sale can be found here. In the last three months, insiders sold 98,210 shares of company stock worth $1,846,548. 21.00% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: This news story was posted by BBNS and is the sole property of of BBNS. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://baseballnewssource.com/2018/03/13/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-intra-cellular-therapies-itci-share-price/2022541.html.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.